Aprea Therapeutics Inc APRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.74
- Day Range
- $0.73–0.77
- 52-Week Range
- $0.55–2.22
- Bid/Ask
- $0.73 / $0.74
- Shares Outstanding
- 12.38M
- Market Cap
- $9.05M
- Volume/Avg
- 24,846 / 361,578
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.aprea.com
Valuation
|
Metric
|
APRE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.21 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
APRE
Financial Strength
|
Metric
|
APRE
|
|---|---|
Quick Ratio | 8.77 |
Current Ratio | 8.92 |
Interest Coverage | — |
Quick Ratio
APRE
Profitability
|
Metric
|
APRE
|
|---|---|
Return on Assets (Normalized) | −49.65% |
Return on Equity (Normalized) | −61.01% |
Return on Invested Capital (Normalized) | −64.11% |
Return on Assets
APRE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ydmlrssdb | Pmppnr | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hkjxkxst | Bgvvmll | $67B | |||
| argenx SE ADR
ARGX
| Lbdmsxrb | Lmxvd | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xdsrczgqx | Wpfxwz | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Xhgpggtft | Tzwsmbm | $25B | |||
| BioNTech SE ADR
BNTX
| Chtbhcd | Kskr | $22B | |||
| Incyte Corp
INCY
| Fjqyxzvf | Rmvh | $20B | |||
| Moderna Inc
MRNA
| Xjdsfrsr | Fghc | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Kjvrtxl | Snlzf | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Wylfzdlsf | Lvcd | $13B |
United States